Clinical trials: Metastatic Childhood Soft Tissue Sarcoma
Soft Tissue Sarcoma
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris administered with doxorubicin in combination, compared with single-agent doxorubicin administered in subjects diagnosed with…
- Trial name
- PICASSO (NCT00718484)
- Testing
- Palifosfamide-Tris, Doxorubicin
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 67 people
- Sponsor
- Alaunos Therapeutics
Sarcoma
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
The purpose of this study is to facilitate access to trabectedin for eligible previously treated patients with soft tissue sarcoma (STS), who cannot be expected to benefit from currently available therapeutic options but who may…
- Trial name
- NCT00210665
- Testing
- Trabectedin
- Where
- 36 sites in United States, Canada and 1 more
- Sponsor
- Janssen Research & Development, LLC
Soft Tissue Sarcoma
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the therapeutic activity and safety of E7389 in patients with advanced/metastatic soft tissue sarcoma who have failed standard chemotherapy.
- Trial name
- NCT00413192
- Testing
- E7389
- Where
- 15 sites in Belgium, Denmark and 3 more
- Volunteers
- 128 people
- Sponsor
- Eisai Inc.
Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
- Trial name
- ADCElerate1 (NCT06797999)
- Testing
- Antibody-drug conjugate (ADC)
- Where
- 9 sites in United States, Belgium and 3 more
- Volunteers
- 270 people
- Sponsor
- Adcendo ApS
Soft Tissue Sarcoma
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
This is a Phase 2, single-arm, Japanese multicenter trial to evaluate the safety, tolerability, and efficacy of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue…
- Trial name
- NCT02255110
- Testing
- TH-302, Doxorubicin
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Soft-tissue Sarcoma
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed…
- Trial name
- NCT05100628
- Testing
- NOX66, Doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Noxopharm Limited
Sarcoma, Soft Tissue
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with locally advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT00061659
- Testing
- ABT-510 - Thrombospondin-1 mimetic
- Where
- 5 sites in United States
- Volunteers
- 88 people
- Sponsor
- Abbott
Sarcoma
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064220
- Testing
- soblidotin
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Daiichi Sankyo
Soft Tissue Sarcoma
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.
- Trial name
- NCT05755113
- Testing
- Tigilanol Tiglate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- QBiotics Group Limited
Soft Tissue Sarcoma
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma…
- Trial name
- FIBROSARC (NCT04650984)
- Testing
- Onfekafusp alfa, Doxorubicin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 102 people
- Sponsor
- Philogen S.p.A.
Soft Tissue Sarcoma
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with…
- Trial name
- PICASSO III (NCT01168791)
- Testing
- Palifosfamide-Tris, doxorubicin
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 447 people
- Sponsor
- Alaunos Therapeutics
Sarcoma, Soft Tissue
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS) by investigating the safety, tolerability, and maximum tolerated dose (MTD)/highest tolerated dose (HTD) of DPPG2-TSL-DOX combined with…
- Trial name
- NCT05858710
- Testing
- DPPG2-TSL-DOX, Dexrazoxane
- Where
- 2 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Thermosome GmbH
Sarcoma, Soft Tissue
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
The primary purpose of the study is to estimate the time from the first dose of LY573636-sodium (hereafter referred to as LY573636) to the date your physician determines that your disease has progressed or worsened.
- Trial name
- NCT00490451
- Testing
- LY573636-sodium
- Where
- 13 sites in United States, Argentina and 1 more
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Sarcoma, Soft Tissue
Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety and efficacy of Pegamotecan (Peg-Camptothecin) in patients with Advanced or Metastatic Soft Tissue sarcoma.
- Trial name
- NCT00079950
- Testing
- Pegamotecan
- Where
- 4 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT03126591
- Testing
- Olaratumab, Pembrolizumab (KEYTRUDA®)
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Leiomyosarcoma
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
- Trial name
- FIBROSARC US (NCT03420014)
- Testing
- Doxorubicin, L19TNF plus doxorubicin
- Where
- 8 sites in United States
- Volunteers
- 114 people
- Sponsor
- Philogen S.p.A.
Sarcoma
A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.
This open-label two-arm study will assess the safety and efficacy of a combination of bevacizumab + standard chemotherapy with standard chemotherapy alone as active comparator in childhood and adolescent patients with metastatic…
- Trial name
- NCT00643565
- Testing
- Standard chemotherapy, bevacizumab [Avastin]
- Where
- 61 sites in Belgium, Brazil and 12 more
- Volunteers
- 154 people
- Sponsor
- Hoffmann-La Roche
Soft Tissue Sarcoma
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
- Trial name
- NCT01440088
- Testing
- TH-302 in Combination with Doxorubicin, Doxorubicin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 640 people
- Sponsor
- Threshold Pharmaceuticals
Soft Tissue Sarcoma
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.
- Trial name
- FLASH (NCT04733183)
- Testing
- Dacarbazine, onfekafusp alfa
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Philogen S.p.A.